Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma von Moskowitz, Craig H., Bastos-Oreiro, Mariana, Ungar, David, Dautaj, Ilva, Kalac, Matko

Volltext

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma von Depaus, Julien, Bryan, Locke J., Ungar, David, Dautaj, Ilva, Wagner-Johnston, Nina D.

Volltext

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Ni... von Ritchie, Ellen K, Catchatourian, Rosalind, Klisovic, Rebecca B., Pinilla-Ibarz, Javier, Deininger, Michael W., Erba, Harry P., Radich, Jerald P., Savona, Michael R., Dautaj, Ilva, Purkayastha, Das, Habucky, Karen, Mauro, Michael J.

Volltext

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who... von Ritchie, Ellen K., Catchatourian, Rose, Klisovic, Rebecca B, Pinilla-Ibarz, Javier, Deininger, Michael W., Erba, Harry P., Radich, Jerald P., Savona, Michael R., Dautaj, Ilva, Wolff, Johannes, Mauro, Michael J.

Volltext

Rapid Achievement of MR4.5 after Switching from Imatinib to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal von Ritchie, Ellen, Deininger, Michael, Erba, Harry, Savona, Michael, Paley, Carole, Dautaj, Ilva, Mauro, Michael

Volltext

Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from... von Ritchie, Ellen K., Catchatourian, Rosalind, Klisovic, Rebecca B., Deininger, Michael W, Erba, Harry P., Radich, Jerald P., Savona, Michael R., Warsi, Ghulam, Paley, Carole S., Dautaj, Ilva, Lin, Felice P., Mauro, Michael J.

Volltext

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) von Berdeja, Jesus G., Heinrich, Michael, Dakhil, Shaker, Goldberg, Stuart L., Wadleigh, Martha, Catchatourian, Rosalind, Kuriakose, Philip, Cortes, Jorge E., Radich, Jerald P., Rizzieri, David A., Bonifacio, Gaetano, Dautaj, Ilva, Warsi, Ghulam, Mauro, Michael J.

Volltext

Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update von Mauro, Michael J., MD, Dakhil, Shaker, MD, Cortes, Jorge E., MD, Rizzieri, David A., MD, Bonifacio, Gaetano, MD, Dautaj, Ilva, Warsi, Ghulam, Heinrich, Michael C., MD, Goldberg, Stuart L., MD, Catchatourian, Rosalind, MD, Kuriakose, Philip, MD, Radich, Jerald, MD

Volltext